rituximab
美 
英
例句
There was no increase in infections or neutropenia with rituximab.
感染和中性粒细胞减少症都没有增加。
Conclusion: Rituximab is a fine and phamacoeconomic choice for non-Hodgkin's lymphoma with satisfactory efficacy and safety.
结论：利妥昔单抗具有较好的疗效和安全性，也是治疗非霍奇金淋巴瘤较经济的方法。
Addition of GM-CSF did not impair tolerance to rituximab, and adverse events were rare and mild.
添加GM-CSF不减弱美罗华的耐受性，不良反应很少，并且很轻。
It is possible to achieve selective depletion of B lymphocytes with rituximab, an anti-CD20 monoclonal antibody.
用抗CD20的单克隆抗体利妥昔单抗能够做到选择性的消耗B淋巴细胞。
Patients get rituximab through infusion into a vein (IV) at the oncologist's office or clinic.
患者可在肿瘤专家的办公室或门诊接受静脉注入美罗华。
The improved efficacy over rituximab monotherapy may be due to increases seen in monocyte, granulocyte, and dendritic cell populations.
与单用美罗华相比，疗效的增加可以通过单核细胞、粒细胞、树突状细胞等群系的增长显现。
Rituximab has been shown to be of therapeutic benefit in various autoimmune diseases in which B lymphocytes play a role.
美罗华已经被证明是治疗中获益的各种自体免疫疾病中，B淋巴细胞发挥作用。
Some experts are already questioning the need for the lymphoma vaccine when a drug, rituximab, exists to control the disease.
一些专家已在质疑，当已经有一种叫美罗华（rituximab）的药能控制淋巴瘤时，是否还要去研究淋巴瘤疫苗。
We observed an aggravation of concomitant cutaneous Kaposi sarcoma, and hypothesize that rituximab could have exacerbated it.
我们观察到的恶化伴随皮肤卡波西氏肉瘤，并推测这种美罗华可能加剧。
Rituximab, an antibody recognizing the CD20 B cell antigen, has proven to be of especially high clinical importance.
美罗华，一个认识到抗CD20抗体的B细胞抗原，已被证明是特别高的临床意义。
Rituximab in combination with chemotherapy resulted in durable remission in a heavily pretreated subgroup.
利妥昔单抗联合化疗可使既往多次化疗的患者获得持续缓解。
Objective To evaluate the efficacy and toxicity of combination of Rituximab and CHOP regimen in diffuse large B-cell lymphoma(DLBCL).
目的观察利妥昔单抗联合CHOP方案（R-CHOP）治疗初治弥漫大B细胞型淋巴瘤的疗效以及毒副反应。
Rituximab may be effective in controlling MCD in a subset of patients.
美罗华可有效地控制麦当劳中的一个子集的患者。
Rituximab specifically recognizes and attaches to a protein called CD20 that is found on the surface of some lymphocytes.
美罗华特异的识别和附着于在一些淋巴细胞表面可以找到蛋白CD20。
Objective: To elucidate the efficacy and adverse drug reaction of rituximab in treatment of non-Hodgkin's lymphoma.
目的：阐述利妥昔单抗对于非霍奇金淋巴瘤的疗效和药物的不良反应，并尝试探讨其药物经济学。
This study was to investigate the efficacy and safety of rituximab-containing regimens for patients with indolent B-cell lymphoma in China.
本研究目的是观察含美罗华方案治疗我国惰性淋巴瘤的疗效和安全性。
The adverse reaction was observed in 11 out of 100 patients during intravenous infusion of rituximab.
100例患者中共有11例因静脉输注利妥昔单抗而发生输液不良反应。
No long-term toxicity potentially due to rituximab was observed.
未见利妥昔单抗的长期潜在毒性。
Rituximab, for instance, can lead to viral infections and heart problems and may be toxic to the kidneys.
以美罗华为例，就可能导致病毒感染和心脏问题，也可能有肾毒性。
Indeed, Dr Huff and Dr Matsui could see stem cells coated with the antibodies alive and well in their samples.
事实上，博士Huff和博士Matsui证实了干细胞能在rituximab包裹的条件下很好的存活。
The rituximab group also had significantly lower levels of glycated hemoglobin and required less insulin.
另外，相对于安慰机组，利妥昔单抗组的糖化血红蛋白和胰岛素必须量都明显较低。
Rituximab may be effective for the treatment of CD20-positive MM.
美罗华可有效地用于治疗抗CD20阳性毫米。
If this coats the myeloma stem cells in the way that rituximab does, the radiation should kill them.
如果这种抗体能像rituximab那样包裹住干细胞，那么标记的放射性将会杀死它们。
Rituximab is a chimeric monoclonal antibody that targets the CD20 molecule on the B-cell surface.
美罗华是一种嵌合单克隆抗体，针对的抗CD20分子的B细胞的表面。
Results At 1 year, the mean AUC for the level of C peptide was significantly higher in the rituximab group than in the placebo group.
结果：一年以后，利妥昔单抗组C肽水平的平均曲线下面积明显高于安慰机组。
Methods 6 elderly patients with B-cell Non-Hodgkin's Lymphoma were treated with Rituximab combined with CTNP regiment in our department.
方法6例经病理证实为B细胞非霍奇金淋巴瘤高龄患者采用美罗华联合CTNP方案化疗。
CD19+ B lymphocytes were depleted in patients in the rituximab group, but levels increased to 69% of baseline values at 12 months.
CD19阳性的B淋巴细胞在利妥昔单抗组里被耗尽，但是在低12个月的时候又回复到基线值的69%。
More patients in the rituximab group than in the placebo group had adverse events, mostly grade 1 or grade 2, after the first infusion.
更多的利妥昔单抗组的患者在第一次注射后发生不良反应，大多数都是1或2级的。
Moreover, AQP4-Ab titres were found to correlate with CD19 cell counts during therapy with rituximab.
而且，我们发现，在利妥昔单抗治疗期间，水通道蛋白4抗体滴度与CD19细胞数相关。
A study of rituximab combined with DICE regimen for treatment of the relapsed or refractory aggressive B-cell Lymphoma
美罗华联合DICE方案治疗复发和难治性侵袭性B细胞淋巴瘤
The Clinical Study of the Regimen of CHOP Plus Rituximab in the Treatment of Refractory Non-Hodgkin's Lymphoma
美罗华联合CHOP方案治疗难治性非霍奇金淋巴瘤的临床研究
The observation of clinical efficacy of rituximab in combination with DHAP chemotherapy in patients with relapsed non-hodgkin lymphoma
利妥昔单抗联合DHAP方案治疗复发性非霍奇金淋巴瘤的临床疗效
Evaluation of rituximab on purgation and mobilization of peripheral blood stem cells in patients with B-cell non-Hodgkin lymphoma
利妥昔单抗净化动员B细胞非霍奇金淋巴瘤外周血干细胞的初步研究
Clinical Analysis of Rituximab Combined with Chemotherapy in Treating Aggressive B-Cell Non-Hodgkin's Lymphoma
美罗华联合化疗治疗侵袭性B细胞性非霍奇金淋巴瘤的临床分析
Efficacy of Rituximab-containing Salvage Regimens on Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
含美罗华联合方案治疗复发耐药B细胞性非霍奇金淋巴瘤
Rituximab and rituximab plus CHOP regimen: adverse reactions and management
利妥昔单抗及其联用CHOP方案的不良反应和处理
Efficacy of Rituximab-containing Regimens on Indolent B-cell Lymphoma--a Report of 34 Cases
含美罗华方案治疗B细胞性惰性淋巴瘤34例报告
Advances of rituximab in the treatment of malignant lymphoma
利妥昔单抗治疗恶性淋巴瘤的进展
Clinical advances in the treatment of B-cell lymphoma by rituximab
B细胞淋巴瘤治疗新药美罗华临床研究进展
